

## **Uriach receives Health Canada approval for rupatadine**

- **Rupatadine**, one of the leading drugs in **Uriach**'s portfolio, has received approval from the Canadian healthcare authority for its two formulations —tablets and paediatric oral solution

**Barcelona, July 22, 2016** – **Uriach**'s international growth has been boosted by approval of rupatadine in Canada, including both tablets and the paediatric solution, for patients with allergic rhinitis and urticaria. This is the culmination of a joint project with Pediapharm, a pharmaceutical company specialising in paediatric products, which began with the signing of the licensing agreement in 2014. The agreement established a series of development milestones spanning from the preparation and submission of the registration dossier to the approval and subsequent marketing of rupatadine. **Uriach** will manufacture the medicinal product at its production site in Palau-solità i Plegamans.

**Rupatadine** will benefit from eight and a half years of market exclusivity granted by Health Canada's Office of Patented Medicines. The antihistamine market in Canada, where rupatadine will be sold, is worth an estimated \$130 mn. It will be the first prescription antihistamine to be launched in the last decade with such a solid clinical evidence base for all forms of allergic rhinitis and urticaria, with formulations for children aged 2 years or more and adults and adolescents.

The **Uriach** CEO Oriol Segarra pointed out that "pursuing our expansion on the international market and increasing rupatadine's worldwide presence are two of the company's strategic objectives, and this milestone is a key step in that direction. We started in 2014 with a far-reaching agreement in Japan, the biggest antihistamine market in the world, and we are closing 2016 with Canadian approval to sell the product on the Canadian market jointly with Pediapharm. In short, we are very pleased with this new step because we think Pediapharm has the necessary experience, resources and know-how to make rupatadine successful in Canada".

The new agreement boosts the internationalisation of **Uriach**, which already sells its products in over 70 countries around the world.

### About Uriach

Uriach is a family-owned pharmaceutical company in the business of improving the health, quality of life and well-being of people all around the world. The company has four business areas: Consumer Health (OTC and Natural Care products), Branded Products, Uriach Generics and Contract Manufacturing. The group, already present in Spain, Italy and Portugal, is expanding internationally and currently operates in more than 70 countries.

The company was set up in 1838 and since then has followed a sustainable and profitable business model. Uriach currently has 700 professionals working at two production centres in the province of Barcelona. The centres carry out in-house production and also manufacture chemical and pharmaceutical products for third parties.

In 2015, its turnover was close to €132 mn, 48% of which came from international sales.

### About Pediapharm

Pediapharm is the only Canadian pharmaceutical company dedicated to serving the needs of the paediatric community. Since its debut in 2008, its mission has been to improve the health and wellbeing of children by purchasing innovative, cutting-edge products. It continues to pursue this objective by entering into commercial agreements with companies from Canada and other countries around the world.

**Belén Badia**

**Communications Director**

belen.badia@uriach.com  
+34 938 360 139  
+34 619 688 199

**Communications Manager**

**Oriol Giménez**

oriol.gimenez@uriach.com  
+34 938 360 187  
+34 635 565 045

**Press Office**

**LEWIS**

uriach@teamlewis.com  
+34 93 222 00 25  
+ 34 610 455 346